The Commission’s recent musings on the social dimension of Europe touches on common drug pricing among member states. But it misses out on solutions for faster access to medicine, Fred Roeder.
Unless the European Commission changes its attitude, the innovation gap between Europe and the US will likely increase, and it could be overtaken soon by China, with dire consequences for living standards, warns Philip Stevens.
An upcoming assessment by a European Commission committee on the risks of UV radiation and sunbeds is hamstrung by in-built bias and a failure to comprehensively address all the issues, warns Frank Harbusch.
The UK's vote to leave the European Union has come at a crucial moment in the development of an international medical project that throws into sharp relief the state of flux Brexit has cast over collaborative research, says Jack Barton.
The most contentious political questions in the Clinical Trials Directive relate to disclosure – whether, how and when the results of clinical trials should be made public and whether pharmaceutical companies can claim ownership over the data generated by them. But if anyone owns the results of clinical trials it is the volunteers who participated, writes Jim Murray.
A cure for clinical trials "Pharma companies often miss their deadlines when testing new drugs. The use of marketing techniques to manage the recruitment of patients for clinical trials could speed things up considerably." The McKinsey Quarterly, 2002 Number 2 Policy relevance: The EU …
